目的 本研究拟通过回顾性研究探讨 IDH1、MGMT、p53 在术后同步放化疗原发性胶质母细 胞瘤（primary glioblastoma，pGBM）中的表达并对其预后进行分析以期指导胶质母细胞瘤患者的个体化、精准化治疗。方法 通过电子病历系统获取 2014 年 1 月至 2018 年 6 月我院及郑大一附院收治的 107 例术后同步放化疗 pGBM 患者的临床资料及 IDH1 基因、MGMT 启动子甲基化、p53 蛋白表达情况。使用 SPSS 21.0 统计学软件进行统计学分析。结果 术后同步放化疗 pGBM 患者 IDH1 突变、mMGMT 和 p53 蛋白阳性表 达率分别为 9.34%、31.78%、15.89%。年龄≤ 55 岁、非功能区、IDH1 突变的术后同步放化疗 pGBM 患者具 有更长的无进展生存期（progression⁃free survival，PFS）和总生存期（overall survival，OS）（P < 0.05）。结论 IDH1、肿瘤部位、年龄为术后同步放化疗 pGBM 患者预后影响因素。IDH1 突变预示术后同步放化疗 pGBM 患者具有更长的PFS 和OS，是预测患者预后的重要分子标志物。

Objective To explore the expression of IDH1，MGMT，and p53 in primary glioblastoma（pGBM） after postoperative concurrent radiochemotherapy through a retrospective study and analyze its prognosis in order to provide the patients with individualized and precise treatment. Methods The clinical data，IDH1 gene，MGMT promoter methylation，and p53 protein expression of 107 pGBM patients admitted to our hospital and Zhengda First Affiliated Hospital for concurrent radiochemotherapy from January 2014 to June 2018 through the electronic medical record system. Statistical analysis was performed using SPSS 21.0. Results The positive expression rates of IDH1 mutation，mMGMT and p53 protein in the pGBM patients with concurrent radiochemotherapy were 9.34%，31.78%， and 15.89%，respectively. The pGBM patients with age ≤ 55，non⁃functional area，IDH1 mutation and concurrent radiochemotherapy had longer progression ⁃free survival（PFS）and overall survival（OS）（P < 0.05）. Conclusion IDH1，tumor location，and age are independent factors affecting the prognosis of pGBM patients with concurrent radiochemotherapy. IDH1 mutation indicates longer PFS and OS in the patients with concurrent radiochemotherapy， and therefore it is an important molecular marker for predicting the prognosis of patients.